Lifestyle intervention to prevent diabetes: Intensive and cost effective

Current Opinion in Lipidology

Volumn 17, Issue 1, 2006, Pages 37-44

  Wylie Rosett, Judith ^a   Herman, William H ^b   Goldberg, Ronald B ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials of lifestyle intervention; Cost benefit analysis; Lifestyle change; Prevention of type 2 diabetes

Indexed keywords

METFORMIN; TROGLITAZONE;

BEHAVIOR MODIFICATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIABETIC OBESITY; DIET THERAPY; DISEASE COURSE; DRUG COST; GLUCOSE TOLERANCE; HEALTH CARE COST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE; LIVER TOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SITTING;

EID: 30744440867     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000203890.27267.eb     Document Type: Review

References (44)

1. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-1297.
2. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898.
3. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28:2472-2479.
4. Pritchett AM, Foreyt JP, Mann DL. Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheroscler Rep 2005; 7:95-102.
5. Jenkins AJ, Rowley KG, Lyons TJ, et al. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10:3395-3418.
6. Jarrett RJ, Keen H, Murrells T. Changes in blood pressure and body weight over ten years in men selected for glucose intolerance. J Epidemiol Community Health 1987; 41:145-151.
7. Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of weight-loss intervention in adults with pre-diabetes. Am J Prev Med 2005; 28:126-139.
8. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20:537-544.
9. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
10. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
11. LiG, Hu Y, Yang W, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002; 58:193-200.
12. Uusitupa M, Lindi V, Louheranta A, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003; 52:2532-2538.
13. Eriksson J, Lindström J, Valle T, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999; 42:793-801.
14. Hamalainen H, Ronnemaa T, Virtanen A, et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 2005; Oct 5; DOI: 10.1007/s00125-005-1938-5 [Epub ahead of print]
15. Uusitipa M. Gene-diet interaction in relation to the prevention of obesity and diabetes; evidence from the Finnish Diabetes Prevention Study. Nutr Metab Cardiovasc Dis 2005; 15:225-233. An interesting review of the findings from the FDPS demonstrating the effects of several genetic polymorphisms on the impact of the lifestyle intervention.
16. Kitabchi AE, Temprosa M, Knowler WC, et al. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54:2404-2414.
17. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular (CVD) risk factors in the Diabetes Prevention Program. Diabetes Care 2005; 28:888-894. This study demonstrated that the prevalence of hypertension and dyslipidemia was reduced by lifestyle intervention compared with the standard care group in the DPP.
18. Diabetes Prevention Program Research Group. Intensive lifestyle or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54:1566-1572. This study from the DPP reported that lifestyle intervention for diabetes prevention has a significant anti-inflammatory effect, more potent than that of metformin, and unlike metformin modestly reduces fibrinogen levels.
19. Orchard TJ, Temprosa M, Goldberg R, et al., for the Diabetes Prevention Program Research Group. Effect of metformin and lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005; 142:611-619. This report demonstrates that lifestyle intervention for diabetes prevention slows the concomitant development of the metabolic syndrome, unlike metformin, which does not.
20. Knowler WC, Hamman RF, Edelstein SL, et al. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54:1150-1156.
21. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of the lifestyle intervention. Diabetes Care 2002; 25:2165-2171.
22. Costacou T, Mayer-Davis EJ, for the Diabetes Prevention Research Group. Nutrition and prevention of type 2 diabetes. Annu Rev Nutr 2003; 23:147-170.
23. Mayer-Davis EJ, Sparks KC, Hirst K, et al., for the Diabetes Prevention Research Group. Dietary intake in the Diabetes Prevention Program cohort: baseline and 1-year post randomization. Ann Epidemiol 2004; 14:763-772.
24. Bazzano LA, Serdula M, Liu S. Prevention of type 2 diabetes by diet and lifestyle modification. J Am Coll Nutr 2005; 24:310-319. This is a useful review of the lifestyle intervention strategies that have been used in type 2 diabetes intervention trials.
25. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293:43-53. This randomized controlled clinical trial compared the 6-month effects of four popular weight loss diets with respect to weight loss and cardiovascular risk markers.
26. Wylie-Rosett J, Segal-Isaacson CJ, Segal-Isaacson A. Carbohydrates and increases in obesity: does the type of carbohydrate make a difference? Obes Res 2004; 12 (Suppl 2):124S-129S.
27. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res 2004; 12 (Suppl):151S-162S.
28. Wing RR, Hamman RF, Bray GA, et al., for the DPP Research Group. Achieving weight and activity goals among Diabetes Prevention Program lifestyle participants. Obes Res 2004; 12:1426-1434.
29. Wylie-Rosett J, Swencionis C, Ginsberg M, et al. Computerized weight loss intervention optimizes staff time: the clinical and cost results of a controlled clinical trial conducted in a managed care setting. J Am Diet Assoc 2001; 101:1155-1162.
30. Wylie-Rosett J, Delahanty L, for the Diabetes Prevention Program Research Group. An integral role of the dietitian: implication of the Diabetes Prevention Program. J Am Diet Assoc 2002; 102:1065-1068.
31. Mossavar-Rahmani Y, Henry H, Rodabough R, et al. Additional self-monitoring tools in the dietary modification component of The Women's Health Initiative. J Am Diet Assoc 2004; 104:76-85.
32. Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005; 82 (Suppl 1):230S-235S. This review paper provides an overview of behavioral interventions that have been successful in weight loss clinical trials.
33. Feinstein RE, Feinstein MS. Psychotherapy for health and lifestyle change. J Clin Psychol 2001; 57:1263-1275.
34. US Department of Agriculture and Department of Health and Human Sevices. 2005 dietary guidelines. Washington, DC: Government Printing Office; 2005.
35. Benjamin SM, Valdez R, Vinicor F. Diabetes prevention (letter). N Engl J Med 2002; 346:1830.
36. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 2003; 26:36-47.
37. The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26:2518-2523.
38. Herman WH, Hoerger TJ, Brandle M, et al., for The Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142:323-332. This DPP analysis provides estimates for the notion that not only may lifetime lifestyle intervention for diabetes prevention be highly cost-effective, but in subjects < 45 years of age, it was estimated to be actually cost-saving.
39. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes mellitus. Diabetes Care 2003; 26:2300-2304.
40. Coffey JT, Brandie M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25:2238-2243.
41. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542-2551.
42. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481.
43. Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004; 26:304-321.
44. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143:251-264.